Last updated on June 2018

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Brief description of study

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.

Detailed Study Description

Coversin, a small protein complement C5 inhibitor which prevents the cleavage of C5 by C5 convertase into C5a and C5b, will be used in an open label, non-comparative clinical trial in patients with PNH and proven resistance to eculizumab due to C5 polymorphisms. Patients will be treated with Coversin by daily subcutaneous injection for 6 months in order to determine the safety and efficacy of the drug in these circumstances. If satisfactory control of the PNH is achieved, and at the discretion of the Principal Investigator (PI), patients will have the option of remaining on Coversin and being entered into the long term follow-up study.

Clinical Study Identifier: NCT02591862

Contact Investigators or Research Sites near you

Start Over

Saskia Langemeijer

Dr Saskia Langemeijer
Nijmegen, Netherlands